Document Detail


Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
MedLine Citation:
PMID:  22958598     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Study Type - Therapy (cost effectiveness analysis) Level of Evidence 2a What's known on the subject? and What does the study add? Bladder cancer is one of the costliest malignancies to treat throughout the life of a patient. The most cost-effective management for low-risk non-muscle-invasive bladder cancer is not known. The current study shows that employing cystoscopic office fulguration for low-risk appearing bladder cancer recurrences can materially impact the cost-effectiveness of therapy. In a follow-up protocol where office fulguration is routinely employed for low-risk bladder cancers, peri-operative intravesical chemotherapy may not provide any additional cost-effectiveness benefit. OBJECTIVE: •  To examine the cost-effectiveness of fulguration vs transurethral resection of bladder tumour (TURBT) with and without perioperative intravesical chemotherapy (PIC) for managing low-risk carcinoma not invading bladder muscle (NMIBC). Low-risk NMIBC carries a low progression rate, lending support to the use of office-based fulguration for small recurrences rather than traditional TURBT. MATERIALS AND METHODS: •  A Markov state transition model was created to simulate treatment of NMIBC with vs without PIC, with recurrence treated by formal TURBT vs treatment with fulguration. •  Costing data were obtained from the Medicare Resource Based Relative Value Scale. •  Data regarding the success of PIC were obtained from the peer-reviewed literature, as were corresponding utilities for bladder cancer-related procedures. •  Sensitivity analyses were performed. RESULTS: •  At 5-year follow-up, a strategy of fulguration without PIC was the most cost-effective (mean cost-effectiveness = US $654.8/quality-adjusted life year), despite a lower recurrence rate with PIC. •  Both fulguration strategies dominated each TURBT strategy. •  Sensitivity analysis showed that fulguration without PIC dominated all other strategies when the recurrence rate after PIC was increased to ≥14.2% per year. •  Similarly, the cost-effectiveness of TURBT becomes more competitive with fulguration when the total cost of TURBT declines < US $1175. CONCLUSIONS: •  The present study shows that fulguration without PIC was the most cost-effective strategy for treating low-risk NMIBC. •  The effectiveness of PIC and the cost of TURBT can materially impact the cost-effectiveness of the different management strategies. •  These results should be considered in treatment decisions in the context of preserving oncological control.
Authors:
David A Green; Michael Rink; Eugene K Cha; Evanguelos Xylinas; Bilal Chughtai; Douglas S Scherr; Shahrokh F Shariat; Richard K Lee
Related Documents :
16909058 - Resolution of intractable hiccups after near-infrared irradiation of relevant acupoints.
24748218 - Chronic inflammation in benign prostate tissue is associated with high-grade prostate c...
25064638 - Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma ri...
24372728 - Prevalence of high-risk human papillomavirus type 16 and 18 in oral and cervical cancer...
11397668 - Phytoestrogens after breast cancer.
16081848 - Spontaneous immunity against bcl-xl in cancer patients.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-7
Journal Detail:
Title:  BJU international     Volume:  -     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 BJU INTERNATIONAL.
Affiliation:
Department of Urology Division of Medical Oncology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY, USA Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Urology, Cochin Hospital, APHP, Paris 5 University, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modifying patterns of movement in people with low back pain -does it help? A systematic review.
Next Document:  Engineered cell-cell communication via DNA messaging.